Drug news
Zerenex Phase III trials in Japan underway
Keryx Biopharmaceuticals announced that its Japanese partner, Japan Tobacco and Torii Pharmaceutical Co., a subsidiary of JT, has commenced the Phase III clinical program of Zerenex (ferric citrate) in Japan for the treatment of patients with hyperphosphatemia. Zerenex (ferric citrate), a ferric iron-based phosphate binder, is also in Phase III clinical development in the US for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease on dialysis.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.